Hier finden Sie die aktuellsten Publikationen aus dem Gebiet der Nuklearmedizin in Österreich. Zusätzlich sind die Publikationen aus den Teilbereichen der PET, SPECT sowie nuklearmedizinischen Therapien unserer Kollegen in Österreich gesondert hervorgehoben.
Rezente Publikationen in Österreich
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA and Herrmann K
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA and Herrmann K
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.
Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer
Al Jalali V, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G and Zeitlinger M
Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer
Al Jalali V, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G and Zeitlinger M
The present study set out to investigate if PET imaging can be used as a potential substitute for immunohistochemical analysis of tumor samples in prostate cancer (PC) patients. Correlation between imaging signals of two PET tracers and the corresponding target structures was assessed. The first tracer was [Ga]Ga-PSMAHBED-CC([Ga]PSMA), which is already implemented in clinical routine. The second tracer was [F]-fluoro-5α-dihydrotestosterone([F]FDHT) which binds to the androgen receptor (AR). The AR is particularly interesting in PC, since the AR expression status and its shift during therapy might directly influence patient care. This prospective, explorative clinical study included 10 newly diagnosed PC patients. Each patient received a [Ga]PSMA-PET/MRI- and [F]FDHT-PET/MRI-scan prior to prostatectomy. Cancer standardized uptake values (SUV) were determined and related to background SUVs. Following prostatectomy, tumor tissue was sampled and AR and prostate-specific membrane antigen (PSMA) expression determined. AR and PSMA expressions were evaluated quantitively with QuPath and additionally with a four-tiered rating system. Correlation between imaging signals and marker expression was statistically assessed. For [F]FDHT, the SUV/SUVbackground ratio showed a significant, strong correlation (P-value=0.019, r=0.72) with AR optical density of the correlating tissue sample. The correlation between PSMA optical density and the [Ga]PSMA SUV/SUVbackground ratio was not significant (P-value=0.061), yet a positive correlation trend could be observed (r=0.61). SUV/SUVbackground ratios were higher for [Ga]PSMA (34.9±24.8) compared to [F]FDHT (4.8±1.2). In line with this findings, the tumor detection rate of the Ga-PSMA-PET scan was 90%, but only 40% for the [F]FDHT-PET scan. The four-tiered rating of PSMA staining intensity yielded very homogenous results with values of 3+ for most subjects (90%). The AR staining was rated with 1+ in two patients (20%), with 2+ in four patients (40%) and with 3+ in four patients (40%). [F]FDHT-PET may be useful for monitoring AR expression and alterations of AR expression during treatment of PC patients. This may facilitate early detection of treatment resistance and allows for adaptation of therapy to prevent cancer progression. [F]FDHT-PET is inferior to [Ga]PSMA-PET for primary PC diagnosis, but the correlation between [Ga]PSMA SUVs and PSMA expression is weaker compared to [F]FDHT and the AR.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G and Virgolini IJ
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G and Virgolini IJ
PET/CT imaging was performed in patients with advanced medullary thyroid cancer (MTC) with the new Ga-labeled minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (Ga-DOTA-MGS5) to evaluate the cholecystokinin-2 receptor expression status. Six patients with advanced MTC underwent PET/CT imaging with Ga-DOTA-MGS5. From the images acquired one and two hours post injection (p.i.) preliminary data on the biodistribution and tumor targeting properties were evaluated in a retrospective analysis. A total of 87 lesions with increased radiotracer uptake considered malignant (two local recurrence, eight lymph nodes, 27 liver and 50 bone lesions) was detected. In general, radiotracer accumulation in lesions was found higher two hours as compared to one hour p.i. (mean SUV/SUV of 7.2/4.4 versus 6.0/3.6). The preliminary results clearly demonstrate the potential of Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.
The diagnostic value of ictal SPECT - a retrospective, semiquantitative monocenter study
Schulte F, Bitzer F, Gärtner FC, Bauer T, von Wrede R, Baumgartner T, Rácz A, Borger V, von Oertzen T, Vatter H, Essler M, Surges R and Rüber T
The diagnostic value of ictal SPECT - a retrospective, semiquantitative monocenter study
Schulte F, Bitzer F, Gärtner FC, Bauer T, von Wrede R, Baumgartner T, Rácz A, Borger V, von Oertzen T, Vatter H, Essler M, Surges R and Rüber T
Ictal single photon emission computed tomography (SPECT) can be used as an advanced diagnostic modality to detect the seizure onset zone in the presurgical evaluation of people with epilepsy. In addition to visual assessment (VSA) of ictal and interictal SPECT images, postprocessing methods such as ictal-interictal SPECT analysis using SPM (ISAS) can visualize regional ictal blood flow differences. We aimed to evaluate and differentiate the diagnostic value of VSA and ISAS in the Bonn cohort.
Development of in-House Synthesis and Quality Control of [Tc]Tc-PSMA-I&S
Plhak E, Pichler C, Gößnitzer E, Aigner RM and Kvaternik H
Development of in-House Synthesis and Quality Control of [Tc]Tc-PSMA-I&S
Plhak E, Pichler C, Gößnitzer E, Aigner RM and Kvaternik H
Many radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [Tc]Tc-PSMA-I&S, primarily developed for radio-guided surgery, which has been identified for diagnostics of prostate cancer. However, there is no commercial kit approved for the preparation of [Tc]Tc-PSMA-I&S on the market. This work presents an automated process for the synthesis of [Tc]Tc-PSMA-I&S concerning good manufacturing practice (GMP). We used a Scintomics GRP 4 V module, with the SCC software package for programming sequences for this development. The optimum reaction conditions were evaluated in preliminary experiments. The pH of the reaction solution was found to be crucial for the radiochemical yield and radiochemical purity. The validation of [Tc]Tc-PSMA-I&S ( = 3) achieved a stable radiochemical yield of 58.7 ± 1.5% and stable radiochemical purities of 93.0 ± 0.3%. The amount of free [Tc]TcO in the solution and reduced hydrolysed [Tc]TcO was <2%. Our automated preparation of [Tc]Tc-PSMA-I&S has shown reliability and applicability in the clinical setting.
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, Ren C, Hacker M, Zhang T, Wu W, Huo L and Li X
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, Ren C, Hacker M, Zhang T, Wu W, Huo L and Li X
Our aim was to assess the prognostic value of [ Ga]Ga-FAPI-04 positron emission tomography (PET) uptake in PDAC and to evaluate the correlation between in vivo lesional radioactivity with pathological characteristics of pancreatic ductal adenocarcinoma (PDAC).
Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients
Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S and Györke T
Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients
Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S and Györke T
2-[18F]fluoro-2-deoxy-d-glucose PET/computed tomography ([18F]FDG-PET/CT) is a widely used imaging method in the management of diffuse large B-cell lymphomas (DLBCL). Our aim was to investigate the prognostic performance of different PET biomarkers in a multicenter setting.
The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management
Sacco M, Gandaglia G, Aas K, Ceci F, Chiu P, Fankhauser CD, Fournier G, Heiddeger I, Kasivisvanathan V, Kesch C, Maggi M, Martini A, Olivier J, Ploussard G, Preisser F, Puche-Sanz I, Rajwa P, Soeterik T, Thibault C, Valerio M, van den Bergh RCN, Zattoni F, Rivas JG, Moschini M, Gillessen S, Bossi A, Gontero P, Marra G and
The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management
Sacco M, Gandaglia G, Aas K, Ceci F, Chiu P, Fankhauser CD, Fournier G, Heiddeger I, Kasivisvanathan V, Kesch C, Maggi M, Martini A, Olivier J, Ploussard G, Preisser F, Puche-Sanz I, Rajwa P, Soeterik T, Thibault C, Valerio M, van den Bergh RCN, Zattoni F, Rivas JG, Moschini M, Gillessen S, Bossi A, Gontero P, Marra G and
The urological community's opinion over the management of men being found with pathologically positive nodes (pN+) following radical prostatectomy (RP) performed with curative intent after preoperative negative conventional staging (cN0M0) has never been assessed. This remains crucial, especially considering the advent of novel imaging modalities. Our aim was to investigate the current opinion on management of pN+ cN0M0 prostate cancer (PCa) in the European urological community.
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Percutaneous coronary intervention of chronic total occlusion (CTO PCI) is a challenging procedure with high complication rates and, as not yet fully understood long-term clinical benefits. Ischemic symptom relief in patients with high ischemic burden is to date the only established clinical indication to undergo CTO PCI, supported by randomized controlled trials. In this context, current guidelines suggest attempting CTO PCI only in non-invasively assessed viable CTO correspondent myocardial territories, with large ischemic areas. Hence, besides a comprehensive coronary angiography lesion evaluation, the information derived from non-invasive cardiac imaging techniques is crucial to selecting candidates who may benefit from the revascularization of the occluded vessel. Currently, there are no clear recommendations for a non-invasive myocardial evaluation or choice of imaging modality pre-CTO PCI. Therefore, selecting among available options is left to the physician's discretion. As CTO PCI is strongly recommended to be carried out explicitly in experienced centers, full access to non-invasive imaging for risk-benefit assessment as well as a systematic institutional evaluation process has to be encouraged. In this framework, we opted to review the current myocardial imaging tools and their use for indicating a CTO PCI. Furthermore, based on our experience, we propose a cost-effective systematic approach for myocardial assessment to help guide clinical decision-making for patients presenting with chronic total occlusions.
In Vivo Coronary F-Sodium Fluoride Activity: Correlations With Coronary Plaque Histological Vulnerability and Physiological Environment
Wen W, Gao M, Yun M, Meng J, Yu W, Zhu Z, Tian Y, Mou T, Zhang Y, Hacker M, Li S, Yu Y, Li X and Zhang X
In Vivo Coronary F-Sodium Fluoride Activity: Correlations With Coronary Plaque Histological Vulnerability and Physiological Environment
Wen W, Gao M, Yun M, Meng J, Yu W, Zhu Z, Tian Y, Mou T, Zhang Y, Hacker M, Li S, Yu Y, Li X and Zhang X
This prospective study aimed to evaluate the associations between in vivo coronary F-sodium fluoride (F-NaF) positron emission tomography (PET)/computed tomography (CT) activity and ex vivo histological characteristics, to determine whether coronary F-NaF activity is a novel biomarker of plaque pathological vulnerability, and to explore the underlying physiological environment of F-NaF adsorption to vascular microcalcification.
Teilbereich PET
F18-FDG PET/CT in a patient with Antisynthetase Syndrome
Nazerani-Zemann T, Stanzel S, Gstettner C, Aigner RM and Pernthaler B
F18-FDG PET/CT in a patient with Antisynthetase Syndrome
Nazerani-Zemann T, Stanzel S, Gstettner C, Aigner RM and Pernthaler B
More prevalent in women than men, Antisynthetase Syndrome is a rare and poorly defined autoimmune disease associated with interstitial lung disease, polymyositis, and dermatomyositis. In addition to various diagnostic tools, imaging modalities are needed in certain situations. A 42-year-old woman with Anti-Jo-1-positive Antisynthetase Syndrome presented with thoracic muscular pain. She underwent whole-body Fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) to evaluate the total extent of the muscles affected. Depicting symptomatic symmetric myositis of the intercostal muscles, F18-FDG PET/CT additionally revealed unusually extensive fasciitis of the lower extremities.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G and Virgolini IJ
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G and Virgolini IJ
PET/CT imaging was performed in patients with advanced medullary thyroid cancer (MTC) with the new Ga-labeled minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (Ga-DOTA-MGS5) to evaluate the cholecystokinin-2 receptor expression status. Six patients with advanced MTC underwent PET/CT imaging with Ga-DOTA-MGS5. From the images acquired one and two hours post injection (p.i.) preliminary data on the biodistribution and tumor targeting properties were evaluated in a retrospective analysis. A total of 87 lesions with increased radiotracer uptake considered malignant (two local recurrence, eight lymph nodes, 27 liver and 50 bone lesions) was detected. In general, radiotracer accumulation in lesions was found higher two hours as compared to one hour p.i. (mean SUV/SUV of 7.2/4.4 versus 6.0/3.6). The preliminary results clearly demonstrate the potential of Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA and Herrmann K
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA and Herrmann K
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.
Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer
Al Jalali V, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G and Zeitlinger M
Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer
Al Jalali V, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G and Zeitlinger M
The present study set out to investigate if PET imaging can be used as a potential substitute for immunohistochemical analysis of tumor samples in prostate cancer (PC) patients. Correlation between imaging signals of two PET tracers and the corresponding target structures was assessed. The first tracer was [Ga]Ga-PSMAHBED-CC([Ga]PSMA), which is already implemented in clinical routine. The second tracer was [F]-fluoro-5α-dihydrotestosterone([F]FDHT) which binds to the androgen receptor (AR). The AR is particularly interesting in PC, since the AR expression status and its shift during therapy might directly influence patient care. This prospective, explorative clinical study included 10 newly diagnosed PC patients. Each patient received a [Ga]PSMA-PET/MRI- and [F]FDHT-PET/MRI-scan prior to prostatectomy. Cancer standardized uptake values (SUV) were determined and related to background SUVs. Following prostatectomy, tumor tissue was sampled and AR and prostate-specific membrane antigen (PSMA) expression determined. AR and PSMA expressions were evaluated quantitively with QuPath and additionally with a four-tiered rating system. Correlation between imaging signals and marker expression was statistically assessed. For [F]FDHT, the SUV/SUVbackground ratio showed a significant, strong correlation (P-value=0.019, r=0.72) with AR optical density of the correlating tissue sample. The correlation between PSMA optical density and the [Ga]PSMA SUV/SUVbackground ratio was not significant (P-value=0.061), yet a positive correlation trend could be observed (r=0.61). SUV/SUVbackground ratios were higher for [Ga]PSMA (34.9±24.8) compared to [F]FDHT (4.8±1.2). In line with this findings, the tumor detection rate of the Ga-PSMA-PET scan was 90%, but only 40% for the [F]FDHT-PET scan. The four-tiered rating of PSMA staining intensity yielded very homogenous results with values of 3+ for most subjects (90%). The AR staining was rated with 1+ in two patients (20%), with 2+ in four patients (40%) and with 3+ in four patients (40%). [F]FDHT-PET may be useful for monitoring AR expression and alterations of AR expression during treatment of PC patients. This may facilitate early detection of treatment resistance and allows for adaptation of therapy to prevent cancer progression. [F]FDHT-PET is inferior to [Ga]PSMA-PET for primary PC diagnosis, but the correlation between [Ga]PSMA SUVs and PSMA expression is weaker compared to [F]FDHT and the AR.
Development of in-House Synthesis and Quality Control of [Tc]Tc-PSMA-I&S
Plhak E, Pichler C, Gößnitzer E, Aigner RM and Kvaternik H
Development of in-House Synthesis and Quality Control of [Tc]Tc-PSMA-I&S
Plhak E, Pichler C, Gößnitzer E, Aigner RM and Kvaternik H
Many radioactive PSMA inhibitory substances have already been developed for PET diagnostics and therapy of prostate cancer. Because PET radionuclides and instrumentation may not be available, technetium-99 m labelled tracers can be considered as a diagnostic alternative. A suitable tracer is [Tc]Tc-PSMA-I&S, primarily developed for radio-guided surgery, which has been identified for diagnostics of prostate cancer. However, there is no commercial kit approved for the preparation of [Tc]Tc-PSMA-I&S on the market. This work presents an automated process for the synthesis of [Tc]Tc-PSMA-I&S concerning good manufacturing practice (GMP). We used a Scintomics GRP 4 V module, with the SCC software package for programming sequences for this development. The optimum reaction conditions were evaluated in preliminary experiments. The pH of the reaction solution was found to be crucial for the radiochemical yield and radiochemical purity. The validation of [Tc]Tc-PSMA-I&S ( = 3) achieved a stable radiochemical yield of 58.7 ± 1.5% and stable radiochemical purities of 93.0 ± 0.3%. The amount of free [Tc]TcO in the solution and reduced hydrolysed [Tc]TcO was <2%. Our automated preparation of [Tc]Tc-PSMA-I&S has shown reliability and applicability in the clinical setting.
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, Ren C, Hacker M, Zhang T, Wu W, Huo L and Li X
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, Ren C, Hacker M, Zhang T, Wu W, Huo L and Li X
Our aim was to assess the prognostic value of [ Ga]Ga-FAPI-04 positron emission tomography (PET) uptake in PDAC and to evaluate the correlation between in vivo lesional radioactivity with pathological characteristics of pancreatic ductal adenocarcinoma (PDAC).
Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients
Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S and Györke T
Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients
Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S and Györke T
2-[18F]fluoro-2-deoxy-d-glucose PET/computed tomography ([18F]FDG-PET/CT) is a widely used imaging method in the management of diffuse large B-cell lymphomas (DLBCL). Our aim was to investigate the prognostic performance of different PET biomarkers in a multicenter setting.
The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management
Sacco M, Gandaglia G, Aas K, Ceci F, Chiu P, Fankhauser CD, Fournier G, Heiddeger I, Kasivisvanathan V, Kesch C, Maggi M, Martini A, Olivier J, Ploussard G, Preisser F, Puche-Sanz I, Rajwa P, Soeterik T, Thibault C, Valerio M, van den Bergh RCN, Zattoni F, Rivas JG, Moschini M, Gillessen S, Bossi A, Gontero P, Marra G and
The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management
Sacco M, Gandaglia G, Aas K, Ceci F, Chiu P, Fankhauser CD, Fournier G, Heiddeger I, Kasivisvanathan V, Kesch C, Maggi M, Martini A, Olivier J, Ploussard G, Preisser F, Puche-Sanz I, Rajwa P, Soeterik T, Thibault C, Valerio M, van den Bergh RCN, Zattoni F, Rivas JG, Moschini M, Gillessen S, Bossi A, Gontero P, Marra G and
The urological community's opinion over the management of men being found with pathologically positive nodes (pN+) following radical prostatectomy (RP) performed with curative intent after preoperative negative conventional staging (cN0M0) has never been assessed. This remains crucial, especially considering the advent of novel imaging modalities. Our aim was to investigate the current opinion on management of pN+ cN0M0 prostate cancer (PCa) in the European urological community.
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Percutaneous coronary intervention of chronic total occlusion (CTO PCI) is a challenging procedure with high complication rates and, as not yet fully understood long-term clinical benefits. Ischemic symptom relief in patients with high ischemic burden is to date the only established clinical indication to undergo CTO PCI, supported by randomized controlled trials. In this context, current guidelines suggest attempting CTO PCI only in non-invasively assessed viable CTO correspondent myocardial territories, with large ischemic areas. Hence, besides a comprehensive coronary angiography lesion evaluation, the information derived from non-invasive cardiac imaging techniques is crucial to selecting candidates who may benefit from the revascularization of the occluded vessel. Currently, there are no clear recommendations for a non-invasive myocardial evaluation or choice of imaging modality pre-CTO PCI. Therefore, selecting among available options is left to the physician's discretion. As CTO PCI is strongly recommended to be carried out explicitly in experienced centers, full access to non-invasive imaging for risk-benefit assessment as well as a systematic institutional evaluation process has to be encouraged. In this framework, we opted to review the current myocardial imaging tools and their use for indicating a CTO PCI. Furthermore, based on our experience, we propose a cost-effective systematic approach for myocardial assessment to help guide clinical decision-making for patients presenting with chronic total occlusions.
In Vivo Coronary F-Sodium Fluoride Activity: Correlations With Coronary Plaque Histological Vulnerability and Physiological Environment
Wen W, Gao M, Yun M, Meng J, Yu W, Zhu Z, Tian Y, Mou T, Zhang Y, Hacker M, Li S, Yu Y, Li X and Zhang X
In Vivo Coronary F-Sodium Fluoride Activity: Correlations With Coronary Plaque Histological Vulnerability and Physiological Environment
Wen W, Gao M, Yun M, Meng J, Yu W, Zhu Z, Tian Y, Mou T, Zhang Y, Hacker M, Li S, Yu Y, Li X and Zhang X
This prospective study aimed to evaluate the associations between in vivo coronary F-sodium fluoride (F-NaF) positron emission tomography (PET)/computed tomography (CT) activity and ex vivo histological characteristics, to determine whether coronary F-NaF activity is a novel biomarker of plaque pathological vulnerability, and to explore the underlying physiological environment of F-NaF adsorption to vascular microcalcification.
Teilbereich SPECT
The diagnostic value of ictal SPECT - a retrospective, semiquantitative monocenter study
Schulte F, Bitzer F, Gärtner FC, Bauer T, von Wrede R, Baumgartner T, Rácz A, Borger V, von Oertzen T, Vatter H, Essler M, Surges R and Rüber T
The diagnostic value of ictal SPECT - a retrospective, semiquantitative monocenter study
Schulte F, Bitzer F, Gärtner FC, Bauer T, von Wrede R, Baumgartner T, Rácz A, Borger V, von Oertzen T, Vatter H, Essler M, Surges R and Rüber T
Ictal single photon emission computed tomography (SPECT) can be used as an advanced diagnostic modality to detect the seizure onset zone in the presurgical evaluation of people with epilepsy. In addition to visual assessment (VSA) of ictal and interictal SPECT images, postprocessing methods such as ictal-interictal SPECT analysis using SPM (ISAS) can visualize regional ictal blood flow differences. We aimed to evaluate and differentiate the diagnostic value of VSA and ISAS in the Bonn cohort.
Imaging of heart disease in women: review and case presentation
Mikail N, Rossi A, Bengs S, Haider A, Stähli BE, Portmann A, Imperiale A, Treyer V, Meisel A, Pazhenkottil AP, Messerli M, Regitz-Zagrosek V, Kaufmann PA, Buechel RR and Gebhard C
Imaging of heart disease in women: review and case presentation
Mikail N, Rossi A, Bengs S, Haider A, Stähli BE, Portmann A, Imperiale A, Treyer V, Meisel A, Pazhenkottil AP, Messerli M, Regitz-Zagrosek V, Kaufmann PA, Buechel RR and Gebhard C
Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide. Although major diagnostic and therapeutic advances have significantly improved the prognosis of patients with CVD in the past decades, these advances have less benefited women than age-matched men. Noninvasive cardiac imaging plays a key role in the diagnosis of CVD. Despite shared imaging features and strategies between both sexes, there are critical sex disparities that warrant careful consideration, related to the selection of the most suited imaging techniques, to technical limitations, and to specific diseases that are overrepresented in the female population. Taking these sex disparities into consideration holds promise to improve management and alleviate the burden of CVD in women. In this review, we summarize the specific features of cardiac imaging in four of the most common presentations of CVD in the female population including coronary artery disease, heart failure, pregnancy complications, and heart disease in oncology, thereby highlighting contemporary strengths and limitations. We further propose diagnostic algorithms tailored to women that might help in selecting the most appropriate imaging modality.
Nuclear medicine imaging methods as novel tools in the assessment of pulmonary drug disposition
Mairinger S, Hernández-Lozano I, Zeitlinger M, Ehrhardt C and Langer O
Nuclear medicine imaging methods as novel tools in the assessment of pulmonary drug disposition
Mairinger S, Hernández-Lozano I, Zeitlinger M, Ehrhardt C and Langer O
Drugs for the treatment of respiratory diseases are commonly administered by oral inhalation. Yet surprisingly little is known about the pulmonary pharmacokinetics of inhaled molecules. Nuclear medicine imaging techniques (i.e. planar gamma scintigraphy, single-photon emission computed tomography [SPECT] and positron emission tomography [PET]) enable the noninvasive dynamic measurement of the lung concentrations of radiolabeled drugs or drug formulations. This review discusses the potential of nuclear medicine imaging techniques in inhalation biopharmaceutical research.
Current status of nuclear cardiology practice in Latin America and the Caribbean, in the era of multimodality cardiac imaging approach: 2022 update
Peix A, Mesquita CT, Gutiérrez C, Puente A, Dueñas-C KA, Massardo T, Berrocal I, Astesiano A, Agüero RN, Bañolas R, Hiplan E, Sánchez M, Barreda AM, Gómez VV, Fernández C, Portillo S, Herrera Y, Mendoza A, Kapitan M, Castellanos C, Rodríguez DI, Estrada E and Páez D
Current status of nuclear cardiology practice in Latin America and the Caribbean, in the era of multimodality cardiac imaging approach: 2022 update
Peix A, Mesquita CT, Gutiérrez C, Puente A, Dueñas-C KA, Massardo T, Berrocal I, Astesiano A, Agüero RN, Bañolas R, Hiplan E, Sánchez M, Barreda AM, Gómez VV, Fernández C, Portillo S, Herrera Y, Mendoza A, Kapitan M, Castellanos C, Rodríguez DI, Estrada E and Páez D
Cardiovascular diseases (CVDs) are the leading cause of mortality in Latin America and the Caribbean (LAC), with the risk in men being slightly higher than in women. The coronavirus disease 2019 (COVID-19) pandemic caused a significant reduction in the number of cardiac diagnostic procedures globally and in particular in LAC. Nuclear cardiology is available in the region, but there is variability in terms of existing technology, radiopharmaceuticals, and human resources. In the region, there are 2385 single photon emission computed tomography (SPECT) and 315 PET scanners, Argentina and Brazil have the largest number. There is an increasing number of new technologies such as cadmium-zinc-telluride (CZT) cardiac-dedicated gamma cameras, SPECT/computed tomography (CT), and PET/CT. All countries performed myocardial perfusion imaging studies, mainly gated-SPECT; the rest are multi-gated acquisition, mainly for cardiac toxicity; detection of viability; rest gated SPECT in patients with dilated cardiomyopathy, and bone-avid tracer cardiac scintigraphy for transthyretin cardiac amyloidosis diagnosis. Regarding other non-nuclear cardiac imaging modalities, Argentina, Colombia, and Chile have the highest ratio of CT scanners, while Brazil, Argentina, and Chile show the highest ratio of MRI scanners. The development of nuclear cardiology and other advanced imaging modalities is challenged by the high cost of equipment, lack of equipment maintenance and service, insufficient-specific training both for imaging specialists and referring clinicians, and lack of awareness of cardiologists or other referring physicians on the clinical applications of nuclear cardiology. Another important aspect to consider is the necessity of implementing cardiac imaging multimodality training. A joint work of nuclear medicine specialists, radiologists, cardiologists, and clinicians, in general, is mandatory to achieve this goal. National, regional, and international cooperation including support from scientific professional societies such as the American Society of Nuclear Cardiology and Latin American Association of Biology and Nuclear Medicine Societies, cardiological societies, and organizations such as the International Atomic Energy Agency, and Pan American Health Organization, as well as government commitment are key factors in the overall efforts to tackle the burden of cardiovascular diseases in the region.
Community Survey Results Show that Standardisation of Preclinical Imaging Techniques Remains a Challenge
Tavares AAS, Mezzanotte L, McDougald W, Bernsen MR, Vanhove C, Aswendt M, Ielacqua GD, Gremse F, Moran CM, Warnock G, Kuntner C and Huisman MC
Community Survey Results Show that Standardisation of Preclinical Imaging Techniques Remains a Challenge
Tavares AAS, Mezzanotte L, McDougald W, Bernsen MR, Vanhove C, Aswendt M, Ielacqua GD, Gremse F, Moran CM, Warnock G, Kuntner C and Huisman MC
To support acquisition of accurate, reproducible and high-quality preclinical imaging data, various standardisation resources have been developed over the years. However, it is unclear the impact of those efforts in current preclinical imaging practices. To better understand the status quo in the field of preclinical imaging standardisation, the STANDARD group of the European Society of Molecular Imaging (ESMI) put together a community survey and a forum for discussion at the European Molecular Imaging Meeting (EMIM) 2022. This paper reports on the results from the STANDARD survey and the forum discussions that took place at EMIM2022.
Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT/CT and semiquantitative planar parameters
Wollenweber T, Rettl R, Kretschmer-Chott E, Rasul S, Kulterer OC, Kluge K, Duca F, Bonderman D, Hacker M and Traub-Weidinger T
Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT/CT and semiquantitative planar parameters
Wollenweber T, Rettl R, Kretschmer-Chott E, Rasul S, Kulterer OC, Kluge K, Duca F, Bonderman D, Hacker M and Traub-Weidinger T
Bone scintigraphy plays an important role in the diagnosis of cardiac Transthyretin-Related Amyloidosis (ATTR). The mechanism of myocardial tracer accumulation and its dependence over time are not fully understood. Recently, a scintigraphic quantification of the cardiac amyloid deposition has been discussed. Nevertheless, little is known regarding the right time of quantitative imaging.
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization-A Workflow Focusing on Non-Invasive Cardiac Imaging
Hamzaraj K, Kammerlander A, Gyöngyösi M, Frey B, Distelmaier K and Graf S
Percutaneous coronary intervention of chronic total occlusion (CTO PCI) is a challenging procedure with high complication rates and, as not yet fully understood long-term clinical benefits. Ischemic symptom relief in patients with high ischemic burden is to date the only established clinical indication to undergo CTO PCI, supported by randomized controlled trials. In this context, current guidelines suggest attempting CTO PCI only in non-invasively assessed viable CTO correspondent myocardial territories, with large ischemic areas. Hence, besides a comprehensive coronary angiography lesion evaluation, the information derived from non-invasive cardiac imaging techniques is crucial to selecting candidates who may benefit from the revascularization of the occluded vessel. Currently, there are no clear recommendations for a non-invasive myocardial evaluation or choice of imaging modality pre-CTO PCI. Therefore, selecting among available options is left to the physician's discretion. As CTO PCI is strongly recommended to be carried out explicitly in experienced centers, full access to non-invasive imaging for risk-benefit assessment as well as a systematic institutional evaluation process has to be encouraged. In this framework, we opted to review the current myocardial imaging tools and their use for indicating a CTO PCI. Furthermore, based on our experience, we propose a cost-effective systematic approach for myocardial assessment to help guide clinical decision-making for patients presenting with chronic total occlusions.
Neurometabolism and Ventricular Dyssynchrony in Patients With Heart Failure and Reduced Ejection Fraction
Bai Y, Yun M, Nie B, Shan L, Liu W, Hacker M, Nie S, Zhou Y, Li S, Shan B, Zhang X and Li X
Neurometabolism and Ventricular Dyssynchrony in Patients With Heart Failure and Reduced Ejection Fraction
Bai Y, Yun M, Nie B, Shan L, Liu W, Hacker M, Nie S, Zhou Y, Li S, Shan B, Zhang X and Li X
The brain coordinates the heart through the autonomic nervous system (ANS). Numerous mediator signals along the brain-heart axis interact with the neuronal-metabolic system in heart failure (HF). Disturbances in cardio-neural interactions influence the disease progression in patients with HF.
Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis
Zhao M, Calabretta R, Yu J, Binder P, Hu S, Hacker M and Li X
Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis
Zhao M, Calabretta R, Yu J, Binder P, Hu S, Hacker M and Li X
Cardiac amyloidosis (CA) is a heterogeneous group of diseases in which extracellular insoluble amyloid proteins are deposited in specific organs and tissues locally or systemically, thereby interfering with physiological function. Transthyretin protein (TTR) and light chain (AL) amyloidosis are the most common types of cardiac amyloidosis. Radionuclide bone scintigraphy has recently become the most common non-invasive test for the diagnosis of TTR-CA but is of limited value for the diagnosis of AL-CA. PET has proved promising for the diagnosis of CA and its applications are expected to expand in the future. This review summarizes the current bone scintigraphy and amyloid-targeting Positron emission tomography (PET) imaging, the binding imaging properties of radiotracers, and the values of diagnosis, prognosis, and monitoring therapy response in CA.
Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?
Wollenweber T, Kretschmer-Chott E, Wurm R, Rasul S, Kulterer O, Rettl R, Duca F, Bonderman D, Sühs KW, Hacker M and Traub-Weidinger T
Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?
Wollenweber T, Kretschmer-Chott E, Wurm R, Rasul S, Kulterer O, Rettl R, Duca F, Bonderman D, Sühs KW, Hacker M and Traub-Weidinger T
With the introduction of several drugs for the therapy of transthyretin-related amyloidosis (ATTR) which slow down the disease, early detection of polyneuropathy (PNP) is becoming increasingly of interest. [99mTc]-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (DPD) bone scintigraphy, which is used for the diagnosis of cardiac (c)ATTR, can possibly make an important contribution in the identification of patients at risk for PNP.
Teilbereich Nuklearmedizinische Therapie
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR and Ilhan H
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR and Ilhan H
Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Toyohara J, Al-Qahtani M, Huang YY, Cazzola E, Todde S, Furumoto S, Mikolajczak R, Decristoforo C, Gillings N, Yang M, Reilly R, Duatti A, Denkova A, Schirrmacher R, Carlucci G, Seimbille Y, Liu Z, Ellis B, Cornelissen BT, Kopka K and Bernardes E
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Toyohara J, Al-Qahtani M, Huang YY, Cazzola E, Todde S, Furumoto S, Mikolajczak R, Decristoforo C, Gillings N, Yang M, Reilly R, Duatti A, Denkova A, Schirrmacher R, Carlucci G, Seimbille Y, Liu Z, Ellis B, Cornelissen BT, Kopka K and Bernardes E
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
Askari E, Moghadam SZ, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CM, Walter MA, Capoccetti F, Kasi PM and Strosberg J
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
Askari E, Moghadam SZ, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CM, Walter MA, Capoccetti F, Kasi PM and Strosberg J
Merkel cell carcinoma (MCC) is a rare aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic MCC (mMCC), besides immunotherapy, chemotherapy and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors (SSTR). We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. 37 patients with mMCC have received PRRT (1-5 cycles) with Lu- and/or Y-labeled somatostatin analogues (cumulative activity: 1.5-30 GBq). Radiographic response was available in 19 out of 28 patients who received PRRT alone. Six (31.6%) out of 19 patients showed objective responses, from partial to complete responses, and no severe adverse events were reported. Our analysis supports the use of PRRT in mMCC with sufficient SSTR uptake, although the quality of the available evidence is low. Prospective studies in terms of clinical trials are already in development and have started accruing in some parts of the world.
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
Tuncel M, Vrachimis A, Campenni A, de Keizer B, Verburg FA, Kreissl MC, Ovcaricek PP, Geliashvili T and Giovanella L
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
Tuncel M, Vrachimis A, Campenni A, de Keizer B, Verburg FA, Kreissl MC, Ovcaricek PP, Geliashvili T and Giovanella L
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ and Hanna EY
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ and Hanna EY
Olfactory neuroblastoma (ONB) is a rare cancer of the sinonasal region. We provide a comprehensive analysis of this malignancy with molecular and clinical trial data on a subset of our cohort to report on the potential efficacy of somatostatin receptor 2 (SSTR2)-targeting imaging and therapy.
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R and Hubalewska-Dydejczyk A
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R and Hubalewska-Dydejczyk A
The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L and Virgolini IJ
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L and Virgolini IJ
Nephro- and hematotoxicity after peptide receptor radionuclide therapy (PRRT) have been described in multiple studies with heterogeneous cumulative activities, number of cycles or radiolabelled peptides. Though highly differentiated metastasized neuroendocrine tumours (NET) have long progression free survival, they may progress. We analysed long-term side effects in a homogenous treatment schedule in PRRT-patients and their impact on future oncologic treatment in case of progression.
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin Lu-PP-F11N
Grob NM, Schibli R, Béhé M and Mindt TL
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin Lu-PP-F11N
Grob NM, Schibli R, Béhé M and Mindt TL
The cholecystokinin-2 receptor (CCK2R) is an attractive target in nuclear medicine due to its overexpression by different tumors. Several radiolabeled peptidic ligands targeting the CCK2R have been investigated in the past; however, their low stability against proteases can limit their uptake in tumors and metastases. Substitution of single or multiple amide bonds with metabolically stable 1,4-disubstituted 1,2,3-triazoles as amide bond bioisosteres proved a promising strategy for improving the tumor-targeting properties of a truncated analog of minigastrin. In this study, we applied the previously studied structural modifications to improve the pharmacokinetic and pharmacodynamic properties of PP-F11N, a minigastrin analog currently in clinical trials. Novel minigastrins (NMGs) as analogs of PP-F11N with one or two amide bonds substituted by 1,2,3-triazoles were synthesized, radiolabeled with Lu, and subjected to full evaluation in vitro (cell internalization, receptor affinity, stability in blood plasma) and in vivo (stability, biodistribution, SPECT/CT imaging). NMGs with triazoles inserted between the amino acids DGlu-Ala and/or Tyr-Gly showed a significantly increased cellular uptake and affinity toward the CCK2R in vitro. Resistance against the metabolic degradation of the NMGs was comparable to those of the clinical candidate PP-F11N. Imaging by SPECT/CT and biodistribution studies demonstrated a higher uptake in CCK2R-positive tumors but also in the CCK2R-positive stomach. The peptidomimetic compounds showed a slow tumor washout and high tumor-to-kidney ratios. The structural modifications led to the identification of analogs with promising properties for progression to clinical applications in the diagnosis and therapy of CCK2R-positive neoplasms.
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L and Virgolini IJ
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L and Virgolini IJ
Nephro- and hematotoxicity after peptide receptor radionuclide therapy (PRRT) have been described in multiple studies with heterogeneous cumulative activities, number of cycles or radiolabelled peptides. Though highly differentiated metastasized neuroendocrine tumours (NET) have long progression free survival, they may progress. We analysed long-term side effects in a homogenous treatment schedule in PRRT-patients and their impact on future oncologic treatment in case of progression.
Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna
Melhorn P, Kretschmer-Chott E, Wolff L, Haug A, Mazal P, Raderer M and Kiesewetter B
Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna
Melhorn P, Kretschmer-Chott E, Wolff L, Haug A, Mazal P, Raderer M and Kiesewetter B
Different oncological therapies have been approved for small intestinal neuroendocrine tumors (SI-NETs), but relatively little is known about efficacy and long-term outcome outside of phase III trials.